MapLight director receives RSUs and stock options
MapLight Therapeutics director George Pavlov received new equity compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MapLight Therapeutics director George Pavlov received new equity compensation. He was granted 3,932 restricted stock units (RSUs), each representing one share of voting common stock, under the company’s 2025 Equity Incentive Plan. After this award, he directly holds 28,932 shares of voting common stock.
He was also granted a stock option covering 14,902 shares of voting common stock at an exercise price of $28.64 per share, expiring on June 22, 2036. Both the RSUs and the option vest on the earlier of June 23, 2027, or the date of MapLight’s next annual stockholder meeting, subject to his Continuous Service under the non-employee director compensation policy.
Insider Trade Summary
Grant/Award: 18,834 shares
Grant/Award
2 txns
Insider
Pavlov George
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 14,902 | $0.00 | $0.00 |
| Grant/Award | Voting Common Stock | 3,932 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 14,902 contracts (Direct);
Voting Common Stock — 28,932 shares (Direct)
Footnotes (3)
- F1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
- F2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
- F3. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
Key Figures
RSU grant size: 3,932 RSUs
Common shares held after grant: 28,932 shares
Stock option size: 14,902 shares
+4 more
7 metrics
RSU grant size
3,932 RSUs
Restricted stock units granted June 23, 2026 under 2025 Equity Incentive Plan
Common shares held after grant
28,932 shares
Voting common stock directly owned by Pavlov following RSU award
Stock option size
14,902 shares
Underlying voting common stock covered by new option grant
Option exercise price
$28.64 per share
Conversion or exercise price for newly granted stock option
Option expiration
June 22, 2036
Expiration date of Pavlov’s 14,902-share stock option
Vesting date trigger
June 23, 2027
Latest vesting date for RSUs and option, or earlier next annual meeting
Transactions classified as acquisitions
2 transactions
Both RSU and option grants reported with acquire direction (code A)
Key Terms
restricted stock units ("RSUs"), 2025 Equity Incentive Plan, Continuous Service, non-employee director compensation policy, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2025 Equity Incentive Plan financial
"RSUs granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan")"
Continuous Service financial
"subject to the Continuous Service (as defined in the Plan) of the Reporting Person"
non-employee director compensation policy financial
"This grant was made pursuant to the Issuer's non-employee director compensation policy"
stock option financial
"Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did MapLight Therapeutics (MPLT) grant to director George Pavlov?
MapLight Therapeutics granted director George Pavlov 3,932 restricted stock units and a stock option for 14,902 shares. Both awards were issued under the 2025 Equity Incentive Plan as part of the company’s non-employee director compensation policy.
When do George Pavlov’s new RSUs and stock options in MPLT vest?
Both the 3,932 RSUs and the 14,902-share stock option vest on the earlier of June 23, 2027, or MapLight’s next annual stockholder meeting. Vesting requires Pavlov to maintain Continuous Service as defined in the company’s 2025 Equity Incentive Plan.
What is the exercise price and expiration date of George Pavlov’s new MPLT stock option?
The stock option granted to George Pavlov has an exercise price of $28.64 per share and covers 14,902 shares of voting common stock. The option expires on June 22, 2036, giving him a long-dated right to purchase shares once vested.
Are George Pavlov’s new MPLT RSUs and options part of a compensation policy?
Yes. The Form 4 states both the 3,932 RSUs and the 14,902-share stock option were granted under MapLight’s non-employee director compensation policy. They are issued pursuant to the company’s 2025 Equity Incentive Plan, aligning director pay with shareholder interests.
AI-generated analysis. How Rhea-AI works. Not financial advice.
